Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2025-02-04 Investor Presentation
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Immutep Corporate Presentation 39 pages 3.9MB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation from Immutep Limited dated February 2025. It includes extensive information about the company's clinical pipeline, drug candidates, trial phases, collaborations, and market potential. The content is structured as a presentation with slides, forward-looking statements, and detailed scientific and clinical data. There is no indication that this is a regulatory filing, earnings release, or annual report. The document is clearly a presentation aimed at investors or stakeholders to update them on the company's business, strategy, and clinical progress. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-02-04 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 397.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Immutep Quarterly Activities Report & Appendix 4C Q2 FY25' and provides a detailed update on the company's clinical trial progress, regulatory approvals, financial cash flow summary, and corporate changes for the quarter ended 31 December 2024. It includes substantive financial data such as cash flow statements, cash receipts, payments for R&D, G&A, and investing activities, as well as operational updates and management changes. The presence of detailed financial statements and analysis for a quarter strongly indicates this is an Interim / Quarterly Report. The Appendix 4C is a standard quarterly cash flow report required by ASX listing rules, further confirming the quarterly reporting nature. The document is lengthy (15,000 characters) and contains actual financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-01-30 English
Enrolment completed for Ph II trial in Soft Tissue Sarcoma 2 pages 101.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of patient enrolment for a Phase II clinical trial (EFTISARC-NEO) by Immutep Limited. It provides details about the trial, its purpose, and expected future data updates in 2025. There are no financial statements, regulatory filings, or detailed financial data. The document is an update on clinical trial progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement related to clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-01-21 English
Patient Enrolment Completed for INSIGHT-003 2 pages 275.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of patient enrolment in a clinical trial (INSIGHT-003) by Immutep Limited. It provides background on the trial, mentions previous data results, and outlines expectations for future data updates. There are no financial statements, regulatory filings, or detailed financial data. The document is an update on clinical trial progress rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement related to clinical trial progress and data updates, which is best categorized under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-01-05 English
Immutep announces initial safety data from IMP761 phase 1 2 pages 106.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing initial safety data from a Phase I clinical trial of IMP761 by Immutep Limited. It discusses clinical trial results, safety profile, and future data expectations. There are no financial statements, regulatory certifications, or detailed financial analysis. The content focuses on clinical trial progress and safety data rather than financial performance or regulatory filings. It is not an earnings release, annual report, or regulatory filing. The document is an update on clinical trial progress and safety data, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-12-16 English
Notification of cessation of securities - IMM 4 pages 14.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights securities for IMMUTEP LIMITED. It provides specific information about securities that have ceased, including quantities and reasons for cessation. The document is a formal announcement to the ASX about changes in the company's issued capital, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of a capital change event related to securities. Therefore, the document fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation of securities.
2024-12-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.